TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.

Autor: Takahashi S; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Sato N; Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan., Kaneko K; Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan., Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Kawai M; Department of Breast Surgery, Miyagi Cancer Center Hospital, Miyagi, Japan; Department of Surgery I, Yamagata University Graduate School of Medical Science, Yamagata, Japan., Hirakawa H; Department of Surgery, Tohoku Kosai Hospital, Sendai, Japan., Nomizu T; Department of Surgery, Hoshi General Hospital, Fukushima, Japan., Iwata H; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Ueda A; Department of Breast Oncology and Surgery, Tokyo Medical University Hospital, Tokyo, Japan., Ishikawa T; Department of Breast Oncology and Surgery, Tokyo Medical University Hospital, Tokyo, Japan., Bando H; Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan., Inoue Y; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Ueno T; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Ohno S; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Kubo M; Department of Breast Surgical Oncology, Kyushu University Hospital, Kyushu University, Fukuoka, Japan., Yamauchi H; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan., Okamoto M; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Tokunaga E; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Kamigaki S; Department of Surgery, Sakai Municipal Hospital, Sakai, Japan., Aogi K; Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan., Komatsu H; Department of Surgery, Iwate Medical University School of Medicine, Shiwa, Japan., Kitada M; Breast Disease Center, Asahikawa Medical University Hospital, Asahikawa, Japan., Uemoto Y; Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Toyama T; Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Yamamoto Y; Department of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto, Japan., Yamashita T; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan., Yanagawa T; Department of Breast Surgery, Kansai Rosai Hospital, Amagasaki, Japan., Yamashita H; Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan., Matsumoto Y; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan., Toi M; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan., Miyashita M; Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Ishida T; Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan., Fujishima F; Department of Pathology, Tohoku University Hospital, Sendai, Japan., Sato S; Department of Pathology, Tohoku University Hospital, Sendai, Japan., Yamaguchi T; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan., Takahashi F; Division of Medical Engineering, Department of Information Science, Iwate Medical University, Yahaba, Japan., Ishioka C; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: chikashi@tohoku.ac.jp.

Publikováno v: Translational oncology [Transl Oncol] 2024 Oct; Vol. 48, pp. 102060. Date of Electronic Publication: 2024 Jul 24.

[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].

Autor: Tsurushima K; Dept. of Pharmacy, Sakai City Medical Center., Yanagishita Y, Ogawa N, Fujii C, Yasui Y, Takeda T, Tsubaki M, Nishida S, Ishizaka T, Yamamura J, Kamigaki S

Publikováno v: Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2022 Jun; Vol. 49 (6), pp. 701-704.

New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.

Autor: Yamamura J; Department of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan. june10th68@gmail.com.; Division of Breast and Endocrine Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohnohigasi, Sayama City, Osaka, 589-8511, Japan. june10th68@gmail.com., Kamigaki S; Department of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan., Fujita J; Department of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan., Osato H; Department of Surgery, Sakai City Medical Center, 1-1-1, Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan., Manabe H; Division of Breast and Endocrine Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohnohigasi, Sayama City, Osaka, 589-8511, Japan., Tanaka Y; Division of Breast and Endocrine Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohnohigasi, Sayama City, Osaka, 589-8511, Japan., Shinzaki W; Division of Breast and Endocrine Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohnohigasi, Sayama City, Osaka, 589-8511, Japan., Hashimoto Y; Division of Breast and Endocrine Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohnohigasi, Sayama City, Osaka, 589-8511, Japan., Komoike Y; Division of Breast and Endocrine Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2, Ohnohigasi, Sayama City, Osaka, 589-8511, Japan.

Publikováno v: BMC cancer [BMC Cancer] 2021 Apr 29; Vol. 21 (1), pp. 476. Date of Electronic Publication: 2021 Apr 29.

Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study).

Autor: Shoji, Tadahiro¹ (AUTHOR) tshoji@iwate-med.ac.jp, Takatori, Eriko¹ (AUTHOR) tnagasaw@iwate-med.ac.jp, Nagasawa, Takayuki¹ (AUTHOR) mkagabu@iwate-med.ac.jp, Kagabu, Masahiro¹ (AUTHOR) babatsu@iwate-med.ac.jp, Baba, Tsukasa¹ (AUTHOR), Shigeto, Tatsuhiko² (AUTHOR) t-shigeto@hirosaki-u.ac.jp, Matsumura, Yukiko² (AUTHOR) y-matsu@hirosaki-u.ac.jp, Shimizu, Dai³ (AUTHOR) shimizud@doc.med.akita-u.ac.jp, Terada, Yukihiro³ (AUTHOR) teraday@doc.med.akita-u.ac.jp, Seino, Manabu⁴ (AUTHOR) m-seino@med.id.yamagata-u.ac.jp, Ohta, Tsuyoshi⁴ (AUTHOR) oota-t@med.id.yamagata-u.ac.jp, Nagase, Satoru⁴ (AUTHOR) nagases@med.id.yamagata-u.ac.jp, Shigeta, Shogo⁵ (AUTHOR) shogo.shigeta.a4@tohoku.ac.jp, Tokunaga, Hideki⁵ (AUTHOR) hideki.tokunaga.a1@tohoku.ac.jp, Shimada, Muneaki⁵ (AUTHOR) muneaki.shimada.b7@tohoku.ac.jp, Kaiho-Sakuma, Michiko⁶ (AUTHOR) michiko-kaihou@miyagi-pho.jp, Furukawa, Shigenori⁷ (AUTHOR) s-furu@infoseek.jp, Soeda, Shu⁷ (AUTHOR) s-soeda@fmu.ac.jp, Watanabe, Takafumi⁷ (AUTHOR) t-wata@fmu.ac.jp, Takahashi, Fumiaki⁸ (AUTHOR) ftakahas@iwate-med.ac.jp

Publikováno v: Cancers. Nov2024, Vol. 16 Issue 22, p3801. 11p.

342P - Response to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: A multicenter study of 236 recurrent metastatic patients

Autor: Yamamura, J., Kamigaki, S., Tsujie, M., Fujita, J., Osato, H., Higashi, C., Kanaizumi, H., Tanaka, Y., Hamada, M., Shinzaki, W., Hasimoto, Y., Komoike, Y.

Publikováno v: In Annals of Oncology October 2018 29 Supplement 8